Essential Fatty Acids in Adult ADHD (OCEAN-GER)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2013 by Saarland University.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
Michael Rösler, Saarland University Identifier:
First received: February 19, 2013
Last updated: February 21, 2013
Last verified: February 2013
The aim of this project is to investigate the effect of a dietary supplementation with essential fatty acids in adults on cognitive functions related to attention and impulse control in the general population and in individuals with a diagnosis of attention deficit hyperactivity disorder (ADHD).

Condition Intervention Phase
Adult Attention Deficit Hyperactivity Disorder
Dietary Supplement: Essential fatty acids
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: The Relationship of Essential Fatty Acids to Cognitive, Electrophysiological and Behavioural Function in Adults With Attention Deficit Hyperactivity Disorder and Controls

Resource links provided by NLM:

Further study details as provided by Saarland University:

Primary Outcome Measures:
  • Wender Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Short and long interval cortical inhibition (SICI and LICI) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Motoric evoced potentials by transcranial magnetic stimulation (TMS)

Other Outcome Measures:
  • Cued continous performance test - QB-version [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 100
Study Start Date: December 2012
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Essential fatty acids
Dietary Supplement: Essential fatty acids
Placebo Comparator: Placebo


Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:


Exclusion Criteria:

  • any acute psychiatric disorder
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01798381

Contact: Michael Rösler, Professor +49 6841 162 6350

Saarland University Hospital Recruiting
Homburg/Saar, Saarland, Germany, D-66421
Contact: Michael Rösler, Professor   
Principal Investigator: Michael Rösler, Professor         
Sponsors and Collaborators
Saarland University
  More Information

Responsible Party: Michael Rösler, Prof. Dr., Saarland University Identifier: NCT01798381     History of Changes
Other Study ID Numbers: OCEAN-GER 
Study First Received: February 19, 2013
Last Updated: February 21, 2013
Health Authority: Germany: Ethics Commission

Additional relevant MeSH terms:
Attention Deficit Disorder with Hyperactivity
Attention Deficit and Disruptive Behavior Disorders
Mental Disorders
Nervous System Diseases
Neurodevelopmental Disorders
Neurologic Manifestations
Signs and Symptoms processed this record on May 23, 2016